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Donna Mayne,g Preeti Pancholi,h Ryan F. Relich,c Richard Thomson,i Nathan A. Ledeboera,b
Medical College of Wisconsin, Milwaukee, Wisconsin, USAa; Dynacare Laboratories, Milwaukee, Wisconsin, USAb; Indiana University School of Medicine, Indianapolis,
Indiana, USAc; Washington University School of Medicine, St. Louis, Missouri, USAd; Wishard Memorial Hospital, Indianapolis, Indiana, USAe; Montefiore Medical Center,
Bronx, New York, New York, USAf; Sacred Heart Hospital, Pensacola, Florida, USAg; The Ohio State University Wexner Medical Center, Columbus, Ohio, USAh; NorthShore
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A bloodstream infection with Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA), is a serious condition that
carries a high mortality rate and is also associated with significant hospital costs. The rapid and accurate identification and dif-
ferentiation of methicillin-susceptible S. aureus (MSSA) andMRSA directly from positive blood cultures has demonstrated ben-
efits in both patient outcome and cost-of-care metrics. We compare the next-generation Xpert MRSA/SA BC (Xpert) assay to the
GeneOhm StaphSR (GeneOhm) assay for the identification and detection of S. aureus and methicillin resistance in prospectively
collected blood culture broths containing Gram-positive cocci. All results were compared to routine bacterial culture as the gold
standard. Across 8 collection and test sites, the Xpert assay demonstrated a sensitivity of 99.6% (range, 96.4% to 100%) and a
specificity of 99.5% (range, 98.0% to 100%) for identifying S. aureus, as well as a sensitivity of 98.1% (range, 87.5% to 100%) and
a specificity of 99.6% (range, 98.3% to 100%) for identifyingMRSA. In comparison, the GeneOhm assay demonstrated a sensitiv-
ity of 99.2% (range, 95.2% to 100%) and a specificity of 96.5% (range, 89.2% to 100%) for identifying S. aureus, as well as a sensi-
tivity of 94.3% (range, 87.5% to 100%) and a specificity of 97.8% (range, 96.1% to 100%) for identifyingMRSA. Five of six cul-
tures falsely reported as negative for MRSA by the GeneOhm assay were correctly identified as positive by the Xpert assay, while
one culture falsely reported as negative for MRSA by the Xpert assay was correctly reported as positive by the GeneOhm assay.
Bloodstream infection (BSI) is a serious condition, resulting in500,000 hospitalizations per year in the United States, ac-
counting for up to 11% of intensive care unit admissions (1, 2).
Mortality associated with BSI can range from 25% to 80%, de-
pending on underlying illnesses, and it is higher in nosocomial
versus community-acquired infections (3–5). Bloodstream infec-
tions also carry a high monetary burden, ranging from $36,000 to
$40,000 in additional expenses per patient as a result of prolonged
hospitalization (4–6). The leading causes of community- and hos-
pital-acquired BSI are Staphylococcus aureus, Staphylococcus epi-
dermidis, and various other coagulase-negative Staphylococcus
(CoNS) species (5, 7). Within this group of organisms, infection
with methicillin-resistant S. aureus (MRSA) is most critical and
has been associated with a mortality rate 1.70 to 1.93 times higher
than that of methicillin-susceptible S. aureus (MSSA) strains (8,
9). The outcome of these infections can be positively impacted by
early diagnosis and effective antimicrobial therapy (10–12). Rapid
diagnostic methods, such as peptide nucleic acid fluorescence in
situ hybridization (PNA FISH), matrix-assisted laser desorption
ionization–time of flight mass spectrometry (MALDI-TOF MS),
and nucleic acid amplification and detection have been success-
fully applied to directly analyze positive blood culture broths (13–
17). These techniques reduce the time to the identification of
pathogens, including Staphylococcus spp., by 18 to 48 h compared
to that with conventional culture and biochemical identification
methods. The differentiation of S. aureus from CoNS (commonly
associated with culture contamination or inadequate skin prepa-
ration prior to specimen collection) in blood culture broths can
result in a reduced length of hospital stay, vancomycin usage, and
overall cost of care (13). Further benefits in patient outcome and
cost of care can be achieved using nucleic acid amplification-based
tests to detect and differentiate MRSA from MSSA and CoNS (10).
This enables the optimization of antimicrobial therapy for MRSA
versus MSSA infections (12).
The molecular tests for identification of Staphylococcus spp.,
including MRSA, directly from positive blood culture broths in-
clude the GeneOhm StaphSR assay (BD, Sparks, MD), Verigene
BC-GP (Nanosphere, Northbrook, IL), FilmArray blood culture
identification (BCID) (BioFire, Salt Lake City, UT), and the Xpert
MRSA/SA BC assay (Cepheid, Sunnyvale, CA). Multiplexed as-
says, such as the Verigene BC-GP and FilmArray BCID, employ
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separate probes for detecting S. aureus and mecA, the gene that
confers resistance to methicillin. This approach has proven to be
sensitive for detecting MRSA; however, the independent detection
of these markers can result in false-positive results when a culture
contains both MSSA and a methicillin-resistant CoNS (MR-
CoNS) (14, 18). In contrast, more traditional real-time PCR (RT-
PCR)-based assays, including the GeneOhm StaphSR and Xpert
MRSA/SA BC assays, target the junction of the staphylococcal
cassette chromosome mec element (SCCmec) (a chromosomal
cassette harboring mecA) and orfX in order to specifically identify
MRSA. A benefit to this approach is the ability to discriminate
MRSA from S. aureus and MR-CoNS in mixed cultures. The
Xpert MRSA/SA BC assay contains additional primers and probes
to ensure that mecA is present, reducing the chance of a false-
positive result. Initial evaluations of the performance of the
GeneOhm and Xpert MRSA/SA BC assays reported 98.3% to
100% sensitivity and 98.4% to 99.4% specificity for the identifica-
tion of MRSA (17, 19). A drawback to the use of a surrogate
marker (SCCmec-orfX) for identifying MRSA is the potential for
genetic rearrangements or point mutations that affect either the
SCCmec-orfX primer binding sites or the mecA gene itself, which
can result in false-negative results. Recent studies using pure cul-
tures of previously characterized isolates have reported sensitivi-
ties as low as 50% to 92% for identifying MRSA in simulated blood
cultures, many of which contained the mecC determinant, or as a
result of variant SCCmec types or genetic rearrangements/dele-
tions within the SCCmec cassette (20–23).
We compared the performance of the next-generation Xpert
MRSA/SA BC assay (Xpert) to that of the GeneOhm StaphSR
assay for identifying and detecting S. aureus and methicillin resis-
tance in prospectively collected blood culture broths containing
Gram-positive cocci. The new Xpert MRSA/SA BC assay cartridge
contains all the reagents required to run the assay on-board, and
the time to results is approximately 10 min longer due to changes
in the automated sample processing. The two molecular tests were
compared to routine culture and identification methods using
latex agglutination and cefoxitin disk diffusion tests as the refer-
ence method.
MATERIALS AND METHODS
Study enrollment. Eight clinical centers representing different geo-
graphic locations within the United States participated in a prospective
study to assess the clinical performance of the next-generation Xpert
MRSA/SA BC assay. Each center enrolled blood cultures using BD Bactec
Plus Aerobic/F (BD, Sparks, MD), VersaTREK REDOX 1 (Thermo
Fisher), or bioMérieux BacT/Alert SA Standard Aerobic (bioMérieux, Ha-
zelwood, MO) medium. The cultures that were identified as positive by an
automated blood culture system were Gram stained to confirm the pres-
ence of bacteria. Cultures containing Gram-positive cocci as individual
cells or in clusters were considered for enrollment in the study. The spec-
imens were tested using the next-generation Xpert MRSA/SA BC assay
and the GeneOhm assay, according to the product insert criteria for each
test. Only one blood culture per patient was enrolled to avoid duplicate
analysis of a single bacterial isolate. The study included blood cultures
obtained from both adult and pediatric patients; however, pediatric pa-
tients were not the focus of the study and comprised3% of the cultures
enrolled in the study. To avoid bias, the results from the molecular assays
were not known to the personnel conducting the reference culture
method testing. This study protocol was independently approved by the
institutional review board (IRB) at each clinical center.
Xpert MRSA/SA BC assay. For the Xpert MRSA/SA BC assay, blood
cultures containing Gram-positive cocci were tested within 24 h of culture
positivity if held at room temperature or within 72 h if held at 2 to 8°C. A
50-l aliquot of the specimen was transferred to an elution reagent vial
(provided) and vortexed for 10 s. The entire contents of the elution re-
agent vial were then transferred to an Xpert MRSA/SA BC test cartridge,
which was sealed and inserted into the GeneXpert for analysis. The Xpert
MRSA/SA BC assay targets spa, mecA, and the SCCmec-orfX junction
using proprietary primer and probe sequences. The detection of all 3
targets was interpreted as positive for MRSA. If spa was detected alone or
in conjunction with SCCmec but mecA was not detected, the result was
interpreted as S. aureus (i.e., MSSA). If spa and mecA were detected in the
absence of the SCCmec-orfX junction, the result was also interpreted as S.
aureus (i.e., MSSA). If spa was not detected, the result was interpreted as
negative for S. aureus regardless of SCCmec-orfX and/or mecA being de-
tected.
GeneOhm StaphSR assay. The blood cultures were tested within 48 h
of positivity using the GeneOhm assay. A 2-l aliquot of culture medium
was transferred to a sample buffer tube (provided) and vortexed for 10 s.
Fifty microliters of the homogenized mixture was transferred to a second
tube containing glass beads (provided), vortexed for 5 min to ensure lysis,
and heated to 95°C for 2 min. Following reconstitution, 25 l of reaction
master mix and 3 l of each lysed heat-inactivated sample were added to
individual SmartCycler PCR tubes. Real-time PCR was conducted in the
Cepheid SmartCycler II. The results were interpreted as positive for
MRSA, positive for S. aureus, or negative based upon the detection of
amplicon corresponding to SCCmec-orfX and/or proprietary S. aureus-
specific genetic targets. The specimens generating invalid results (i.e., a
reading of “invalid,” “error,” “no result,” or “unresolved”) on either assay
were repeated once. The specimens generating a second invalid result
were excluded from statistical analysis.
Reference culture method. The blood culture broths were plated to
agar medium containing 5% sheep blood and incubated for 18 to 48 h.
Beta-hemolytic colonies were identified as S. aureus using Gram stain
morphology, a positive catalase test, and positive S. aureus latex aggluti-
nation (BactiStaph; Remel, Lenexa, KS). All isolates identified as S. aureus
were tested for oxacillin/methicillin resistance using the cefoxitin disk
diffusion method in accordance with Clinical and Laboratory Standards
Institute (CLSI) standards M02-A11 (24) and M100-S22 (25). In brief, a
0.5 McFarland suspension of the test strain was plated on Mueller-Hinton
agar (MHA). A 30-g cefoxitin disk was placed onto the plate, and the
culture was incubated aerobically for 16 to 18 h at 35°C, at which point the
zone of inhibition was measured and interpreted (21 mm, resistant;
22 mm, susceptible).
Data analysis. The results for each of the molecular assays were com-
pared to those of the reference culture and antimicrobial susceptibility
testing methods. The sensitivities and specificities were calculated using
standard methods. The 95% confidence interval was determined using the
binomial expansion method. The poolability of the data between sites was
examined using Fisher’s exact test. If P values were0.05, the difference
between the groups was considered to be statistically significant. The sta-
tistical significance between the performance (sensitivity and specificity)
of each assay was established using McNemar’s test (26).
RESULTS
Study population. A total of 795 blood culture broths (468 BD
Bactec Plus Aerobic/F sites A, B, C, F, and H; 197 VersaTREK
REDOX 1 sites D and G; and 130 BacT/Alert SA Standard Aerobic
site E) meeting the study criteria were collected and tested at 8
clinical centers using the Xpert MRSA/SA BC assay. The preva-
lences based on culture-confirmed results were 29.7% (range,
20.8% to 38.6%) for S. aureus and 13.3% (range, 7.0% to 17.6%)
for MRSA. The Xpert MRSA/SA BC assay successfully returned
results for 764/795 broths (96.1%) following the initial test. This
increased to 792/795 (99.6%) broths following a single retest of
the specimens initially reported to be invalid, error, or no result. A
Next-Generation Xpert MRSA/SA BC Assay
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total of 806 specimens (474 BD Bactec Plus Aerobic/F, 197 Versa-
TREK REDOX 1, and 135 BacT/Alert SA Standard Aerobic) were
tested using the GeneOhm assay and reference culture, according
to the study criteria. The GeneOhm assay generated a valid result
for 776/806 (96.3%) specimens on the initial test. A single repeat
test was conducted with 21/30 samples that failed the initial anal-
ysis, of which 6 generated a valid result. The remaining 9 samples
with an initial invalid result were not retested within the time
frame specified by the product insert. This resulted in a final valid
result rate of 782/797 (98.1%).
Identification of S. aureus. The two molecular tests demon-
strated similar sensitivities (Xpert, 99.6%; GeneOhm, 99.2%; P
0.99 to 1.00, Fisher’s exact test) for identifying S. aureus (MRSA
and MSSA) in blood culture broths (Table 1). The sensitivities of
the molecular tests ranged from 95.2% to 100% among the 8 clin-
ical centers; however, the intersite variability for each test was not
statistically significant (P 0.05, Fisher’s exact test). Additionally,
there was not a statistically significant difference in performance
between the three blood culture systems used by the various study
sites. One sample tested falsely negative for S. aureus by the Xpert
assay but it tested positive by the GeneOhm assay (Table 1, site E).
Two samples tested falsely negative by the GeneOhm assay but
were positive for S. aureus by the Xpert assay (Table 1, sites C and
G). The specificity of the Xpert test was 99.5% (553/556), with
three false-positive S. aureus results reported. All three specimens
were also reported as either positive (i.e., MRSA) or reactive (i.e.,
S. aureus) by the GeneOhm assay, all of which matched the corre-
sponding Xpert assay results. The GeneOhm assay was compara-
tively less specific (96.5% [527/546]), reporting 19 false-positive S.
aureus results (P 0.001).
Identification of MRSA. The identification of MRSA in
blood culture broths showed greater variability between the 2
molecular tests (Table 2). The sensitivity of the Xpert assay was
a combined 98.1% (103/105), while the sensitivity of the
GeneOhm assay was 94.3% (99/105). The sensitivity of the
Xpert assay ranged from 87.5% to 100% across the eight clini-
cal centers but was a combined 100% (77/77) at six of the eight
clinical centers. This intersite variability was not statistically
significant (P  0.05, Fisher’s exact test), nor was there a sta-
tistically significant difference in performance between the cul-
ture media. Across all test sites, the Xpert assay reported two
blood cultures to be S. aureus that were confirmed to be MRSA by
the cefoxitin disk diffusion test (i.e., false-negative Xpert assay
results). Also, one of two blood cultures was negative for MRSA by
the GeneOhm assay (Table 3, specimen C039), while the other
tested positive (Table 3, specimen G013). Of note, specimen G013
was reported to contain MRSA by reference culture, while speci-
men C039 was reported to contain both MRSA and MSSA. Across
5 test sites, GeneOhm assay reported 6 cultures to be negative for
MRSA, for a combined sensitivity of 94.3% (range, 87.5% to
100%). All 6 false-negative reports were had a positive result for S.
aureus by the GeneOhm assay only, but 5/6 tested positive for
MRSA by the Xpert assay (Table 3).
The specificity of the Xpert assay for identifying MRSA was
99.6% (684/687), with 3 false-positive results across all 8 test
sites (Table 2). Two of these results were obtained from blood
cultures containing methicillin-susceptible S. aureus; however,
one sample was negative for S. aureus by reference culture, indi-
cating possible contamination or the presence of a nonviable or-
ganism. The specificity of the GeneOhm assay was 97.8% (662/
677). Of the 15 false-positive results for MRSA, 7 blood cultures
contained methicillin-susceptible S. aureus, and 9 were negative
for S. aureus by reference culture.








[95% CI])TP FP TN FN
Xpert MRSA/SA BC A 63 19 0 44 0 100 (82.4–100) 100 (92.0–100)
B 91 32 0 59 0 100 (89.1–100) 100 (93.9–100)
C 44 17 0 27 0 100 (80.5–100) 100 (87.2–100)
D 70 26 0 44 0 100 (86.8–100) 100 (92.0–100)
E 130 27 2c 100 1d 96.4 (79.7–99.8) 98.0 (92.4–99.6)
F 211 65 1e 145 0 100 (94.5–100) 99.3 (96.2–100)
G 126 31 0 95 0 100 (88.8–100) 100 (96.2–100)
H 57 18 0 39 0 100 (81.5–100) 100 (91.0–100)
Total 792 235 3 553 1 99.6 (97.7–99.9) 99.5 (98.4–99.9)
GeneOhm StaphSR A 60 18 0 42 0 100 (81.5–100) 100 (91.6–100)
B 91 32 2 57 0 100 (89.1–100) 96.6 (88.3–99.6)
C 52 20 1 30 1 95.2 (76.2–99.9) 96.8 (73.2–95.8)
D 63 25 0 38 0 100 (86.3–100) 100 (90.7–100)
E 131 28 4 99 0 100 (87.7–100) 96.1 (90.4–98.9)
F 202 64 8 130 0 100 (94.4–100) 94.2 (88.9–97.5)
G 127 30 0 96 1d 96.8 (83.3–99.9) 100 (96.2–100)
H 56 17 4 30 0 100 (80.5–100) 89.7 (75.8–97.1)
Total 782 234 19 527 2 99.2 (97.0–99.9) 96.5 (94.6–97.9)
a TP, true positive; FP, false positive; TN, true negative; FN, false negative.
b CI, confidence interval.
c 1 identified as MRSA and 1 identified as S. aureus (MSSA) by the Xpert MRSA/SA BC assay.
d Identified as MSSA by culture.
e Identified as S. aureus (MSSA) by the Xpert MRSA/SA BC assay.
Buchan et al.
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The next-generation Xpert MRSA/SA BC assay is an on-demand
sample-to-result molecular test for the identification of S. aureus
and MRSA directly from positive blood culture broths. The detec-
tion and differentiation of S. aureus and MRSA are achieved by
incorporating three nucleic acid targets, including the SCCmec-
orfX junction,mecA, and spa. The BD GeneOhm StaphSR test uses
a two-target approach, relying on the detection of the SCCmec-
orfX junction site and an S. aureus species-specific target for the
identification of MRSA (17). The initial clinical evaluations of the
original Xpert MRSA/SA BC assay and the GeneOhm StaphSR test
demonstrated sensitivities of 93.7% to 100% for S. aureus and
98.3% to 100% for MRSA in positive blood culture broths (17, 19,
27). Subsequently, several published reports indicated sensitivities
as low as 50% to 92% for detecting MRSA using the GeneOhm and
Xpert MRSA/SA assays (20–23). These false-negative results were
primarily attributable to mutations in the junction region of
SCCmec-orfX, the target of the GeneOhm assay, or to variant
SCCmec types, including type IVa, which in some institutions
comprise up to 33% of the SCCmec types (20, 22, 23, 28). Addi-
tionally, the specificities of these tests for identifying MRSA suffer
for strains containing truncated SCCmec cassettes or “empty cas-
settes” lacking a functional mecA gene (29, 30). Such strains may
account for up to 4.6% of the S. aureus strains carrying the cassette
(28).
The Next-generation Xpert MRSA/SA BC assay incorporates a
modified sample preparation protocol to improve assay accuracy,
although the specific changes to the assay are not publicly avail-
able. Though not statistically significant, the Xpert MRSA/SA BC
assay demonstrated greater sensitivity than that of the GeneOhm
StaphSR test for identifying MRSA. One of the two false-negative
results reported by the Xpert assay contained both MSSA and
MRSA upon reference culture, and the GeneOhm assay also failed
to identify MRSA in this specimen. Taken together, this might
suggest contamination of the reference culture with MRSA subse-
quent to molecular testing. The specificity of the Xpert MRSA/SA
BC assay was99.5% for both S. aureus and MRSA, which is equal
to or greater than that of the GeneOhm assay. The three specimens
with false-positive results for S. aureus by the Xpert assay were also








(% [95% CI])TP FP TN FN
Xpert MRSA/SA BC A 63 11 0 52 0 100 (71.5–100) 100 (93.2–100)
B 91 16 0 75 0 100 (79.4–100) 100 (95.2–100)
C 44 7 0 36 1 87.5 (47.3–99.7) 100 (90.3–100)
D 70 11 1c 58 0 100 (71.5–100) 98.3 (90.9–100)
E 130 10 1d 119 0 100 (69.2–100) 99.2 (95.4–100)
F 211 25 1c 185 0 100 (86.3–100) 99.5 (97.0–100)
G 126 19 0 106 1 95.0 (73.0–99.7) 100 (96.2–100)
H 57 4 0 53 0 100 (81.5–100) 100 (91.6–100)
Total 792 103 3 684 2e 98.1 (93.3–99.8) 99.6 (98.7–99.9)
GeneOhm StaphSR A 60 10 0 49 1 90.9 (58.7–99.8) 100 (96.4–98.8)
B 91 14 1d 74 2 87.5 (61.7–98.4) 98.7 (92.8–100)
C 52 8 1c 42 1 88.9 (51.8–99.7) 97.7 (87.7–99.9)
D 63 10 0 53 0 100 (69.2–100) 100 (93.3–100)
E 131 10 3f 118 0 100 (69.2–100) 97.5 (92.9–99.5)
F 202 24 7g 170 1 96.0 (79.6–99.9) 96.1 (92.0–98.4)
G 127 19 1c 106 1 95.0 (75.1–99.9) 99.1 (94.9–100)
H 56 4 2h 50 0 100 (39.8–100) 96.2 (86.8–99.5)
Total 782 99 15 662 6i 94.3 (88.0–97.9) 97.8 (96.4–98.8)
a TP, true positive; FP, false positive; TN, true negative; FN, false negative.
b CI, confidence interval.
c Identified as MSSA by culture.
d Negative for S. aureus by culture.
e Identified as S. aureus (MSSA) by the Xpert MRSA/SA BC assay.
f One identified as S. aureus (MSSA), and two negative for S. aureus by culture.
g Two identified as S. aureus (MSSA), and five negative for S. aureus by culture.
h One identified as S. aureus (MSSA), and one negative for S. aureus by culture.
i Identified as S. aureus (MSSA) by GeneOhm assay.
TABLE 3 Specimens resulting in false-negative MRSA calls by the Xpert










A004 None TP FN
B042 8 TP FN
B080 7 TP FN
C039 12, 26d FN FN
F094 10 TP FN
G013 6 FN TP
G022 6 TP FN
a ID, identification.
b Zone of inhibition measured by cefoxitin disk diffusion test.
c TP, true positive; FN, false negative.
d Specimen contained two isolates of S. aureus. One MRSA and one MSSA (showing
12-mm and 26-mm zones of inhibition for cefoxitin, respectively).
Next-Generation Xpert MRSA/SA BC Assay
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detected by the GeneOhm assay, suggesting that the reference cul-
ture results may have been falsely negative for these specimens.
Seven specimens generated false-negative results for MRSA on
at least one of the molecular assays (Xpert MRSA/SA BC, n  2;
GeneOhm, n  6). The possible causes for this include variant
SCCmec cassettes, as previously discussed, the presence of the
mecC resistance determinant, or high-level expression of penicil-
linases leading to borderline oxacillin resistance (31–34). All
strains were confirmed to be phenotypically methicillin resistant,
demonstrating zones of inhibition ranging from undetectable to
14 mm with the cefoxitin disk diffusion test. It is likely that the
resistances in these strains were mediated by mecA as opposed the
overexpression of a penicillinase, which typically results in cefoxi-
tin zones of inhibition of 28 mm (35). MRSA harboring mecC
will display high-level phenotypic resistance to cefoxitin, which is
consistent with the MRSA strains not detected by the GeneOhm
assay in this study. However, all but two of these strains were
correctly identified as MRSA by the next-generation Xpert
MRSA/SA BC assay, effectively ruling this out as an explanation
for the false-negative results. Combined, this suggests that the
false-negative MRSA results observed may have been due to vari-
ant SCCmec types not recognized by the GeneOhm assay.
A strength of this study is the participation of 8 clinical centers
located in different geographic locations within the United States
and the enrollment of a large number of clinical specimens (n 
795), which should account for regional and institutional strain
variability. The clinical performance measures (sensitivity and
specificity) of the next-generation Xpert MRSA/SA BC assay
among all sites were statistically equivalent. This indicates the abil-
ity to accurately identify S. aureus and MRSA strains across differ-
ent geographic locations, accounting for regional and institu-
tional strain diversity. Additionally, these results demonstrate the
ability of the next-generation Xpert MRSA/SA BC assay to gener-
ate equivalent results independent of laboratory variables, includ-
ing different technologists, laboratory workflow practices, and
blood culture media. Another strength of this study is the head-
to-head comparison of the next-generation Xpert MRSA/SA BC
assay with the GeneOhm StaphSR assay, a second commercially
available FDA-cleared molecular test for the identification of S.
aureus and MRSA in positive blood culture broths. Our data dem-
onstrate statistically equivalent performances for these two tests;
however, the workflow was simpler with the Xpert MRSA/SA BC
assay, which required fewer preanalytic processing steps than the
GeneOhm StaphSR and could be conducted on-demand using the
random-access GeneXpert system.
A potential weakness of this study was the inclusion of speci-
mens obtained from clinical centers located only within the
United States. Several of the studies indicating poorer perfor-
mances of the GeneOhm and Xpert assays were conducted in the
European Union or Australia (20, 21, 23). Clinical evaluations of
the redesigned Xpert MRSA/SA BC test in these locations will be
necessary to confirm the improved performance demonstrated in
the current study. Additionally, specimens that tested as false neg-
ative for MRSA were not fully characterized to establish the root
cause of the false-negative result; however, only a single specimen
tested as false negative on both molecular assays, suggesting that
differences in the target and primer design between the tests ac-
counted for the additional false-negative results observed with the
GeneOhm assay. Finally, the specimens were not tested simulta-
neously on both molecular assays. Because the GeneOhm test
lends to batch processing, these tests may have been initiated after
the initiation of the Xpert test. It is possible that delayed testing
negatively impacts results if the specimen contained nucleases that
degrade target sequences or accumulated other inhibitory sub-
stances resulting from specimen degradation. Alternatively, de-
layed testing may increase sensitivity due to additional bacterial
growth. These factors were not evaluated; however, both molecu-
lar tests were performed according to the specimen acceptability
criteria set forth in the respective product insert.
The benefits of the rapid detection of S. aureus and MRSA
directly from positive blood culture broths are well documented.
Specifically, molecular testing for S. aureus and MRSA resulted in
a 21% decrease in the number of patients receiving anti-MRSA
therapy and a mean reduction of 12.2 h in the duration of therapy
for patients with blood cultures containing Gram-positive cocci
that tested negative for S. aureus (36). Likewise, the time to opti-
mal antimicrobial therapy for the patients with cultures positive
for MSSA was reduced by 38.4 to 44.6 h following the implemen-
tation of a molecular test (10, 36). These rapid results contributed
to a mean reduction in the length of hospital stay of 6.2 days and a
reduction of $21,387 in the total hospital cost per septic episode
compared to those of patients diagnosed using routine culture and
susceptibility testing methods (10). Importantly, these advantages
are realized only when molecular testing can be performed on-
demand and the results are actively reported to the clinician. The
use of batched testing formats and passive reporting of results does
not significantly reduce the time to optimal antimicrobial therapy
despite definitive identification of S. aureus and MRSA 13 h
sooner than with culture methods (37). The Xpert and GeneOhm
assays demonstrated statistically equivalent sensitivities and spec-
ificities for identifying S. aureus and MRSA in positive blood cul-
tures compared to those with the culture method. A potential
advantage of the Xpert MRSA/SA BC assay is the simplified sam-
ple-to-result workflow and on-demand capability, which gives it
the potential to reduce the turnaround time for blood cultures
containing S. aureus or MRSA.
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